Search details
1.
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
BMC Cancer
; 23(1): 112, 2023 Jan 31.
Article
in English
| MEDLINE | ID: mdl-36721174
2.
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat
; 188(3): 631-640, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34148205
3.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-34125340
4.
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Lancet Oncol
; 18(7): 917-928, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28592386
5.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Lancet
; 388(10063): 2997-3005, 2016 12 17.
Article
in English
| MEDLINE | ID: mdl-27908454
6.
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
JAMA
; 317(1): 37-47, 2017 01 03.
Article
in English
| MEDLINE | ID: mdl-27918780
7.
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
JCO Glob Oncol
; 10: e2200328, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38237093
8.
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.
Breast Cancer Res Treat
; 137(2): 471-82, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23239151
9.
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
BioDrugs
; 37(3): 433-440, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36881323
10.
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.
Cancer Invest
; 30(4): 309-16, 2012 May.
Article
in English
| MEDLINE | ID: mdl-22468806
11.
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Breast
; 64: 151-158, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35487845
12.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet
; 375(9712): 377-84, 2010 Jan 30.
Article
in English
| MEDLINE | ID: mdl-20113825
13.
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Breast
; 58: 18-26, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33892316
14.
A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Oncology
; 79(1-2): 129-35, 2010.
Article
in English
| MEDLINE | ID: mdl-21088439
15.
A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
Breast Cancer Res Treat
; 110(2): 309-15, 2008 Jul.
Article
in English
| MEDLINE | ID: mdl-17851759
16.
Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Clin Cancer Res
; 13(14): 4185-90, 2007 Jul 15.
Article
in English
| MEDLINE | ID: mdl-17634547
17.
Total pathological complete response versus breast pathological complete response in clinical trials of reference and biosimilar trastuzumab in the neoadjuvant treatment of breast cancer.
Expert Rev Anticancer Ther
; 18(6): 531-541, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29580109
18.
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
J Clin Oncol
; 33(2): 141-8, 2015 Jan 10.
Article
in English
| MEDLINE | ID: mdl-25185099
19.
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
J Clin Oncol
; 33(14): 1564-73, 2015 May 10.
Article
in English
| MEDLINE | ID: mdl-25605838
20.
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
J Clin Oncol
; 33(14): 1574-83, 2015 May 10.
Article
in English
| MEDLINE | ID: mdl-25779558